智通财经APP讯，片仔癀(600436.SH)发布2025年三季度报告，前三季度，公司实现营业收入74.42亿 元，同比下降11.93%。归属于上市公司股东的净利润21.29亿元，同比下降20.74%。归属于上市公司股 东的扣除非经常性损益的净利润18.91亿元，同比下降30.38%。 ...

Core Viewpoint - The Chinese medicine ETF (560080) has shown resilience amidst a broader market decline, with significant trading volume and a notable increase in net inflows, indicating strong investor interest in the sector [1][2][3]. Group 1: Market Performance - The overall market experienced a downward trend, while the consumer sector, particularly the Chinese medicine ETF (560080), demonstrated relative strength, only declining by 1% after three consecutive days of gains [1]. - The trading volume for the Chinese medicine ETF exceeded 170 million yuan, marking a 34% increase compared to the previous day, suggesting active investor engagement [1]. - The Chinese medicine ETF has attracted net inflows of over 240 million yuan in the last ten days, with its total fund size surpassing 2.7 billion yuan, leading its peers significantly [2]. Group 2: Fund and Leverage Insights - The financing balance for the Chinese medicine ETF has reached over 80 million yuan, maintaining a historical high, indicating continued interest from leveraged investors seeking value in the sector [3]. - The ETF's price-to-earnings ratio (TTM) stands at 25.12, which is at the 22.43% percentile over the past decade, suggesting that the index is currently cheaper than 77.57% of the time in the last ten years, enhancing its attractiveness [10]. Group 3: Company-Specific Developments - The company Pizhou Pharmaceutical reported a significant decline in its third-quarter revenue, down 26.28% year-on-year to 2.064 billion yuan, and a net profit drop of 28.82% to 687 million yuan, attributed to reduced sales in the pharmaceutical manufacturing sector and declining gross margins [4]. - The overall performance of the Chinese medicine index remains negative for the year, with a year-to-date decline of 2.26% and a drop of 8.13% in 2024, indicating ongoing challenges in the sector [5][7]. Group 4: Future Outlook - Analysts from Zheshang Securities anticipate an inflection point for the Chinese medicine sector, projecting improved revenue and net profit growth in the second half of 2025, driven by a reduction in cost pressures from declining raw material prices [11][12]. - The recent stabilization of flu data and the return to normal levels of flu-like cases in both northern and southern provinces may alleviate revenue growth pressures for the industry [9].

Core Viewpoint - The company Pianzaihuang has announced the initiation of Phase III clinical trials for its innovative traditional Chinese medicine, Wen Dan Pian, aimed at treating mild to moderate generalized anxiety disorder [1] Group 1: Clinical Development - Wen Dan Pian has completed the enrollment of the first subject in a multi-center, randomized, double-blind, placebo-controlled Phase III clinical trial [1] - The trial evaluates the efficacy and safety of Wen Dan Pian in treating generalized anxiety disorder characterized by phlegm-heat disturbance [1] Group 2: Product Background - Wen Dan Pian is derived from the classic formula Wen Dan Tang, known for its effects in regulating qi, resolving phlegm, and calming the mind [1] - The product has been used clinically as a hospital preparation since 2007 [1]

北京商报讯（记者 王寅浩 实习记者 宋雨盈）10月17日，片仔癀发布公告称，2025年第三季度实现营业 收入20.64亿元，同比下降26.28%；归属于上市公司股东的净利润为6.87亿元，同比下降28.82%；归属 于上市公司股东的扣除非经常性损益的净利润为4.38亿元，同比下降54.6%。2025年前三季度实现营业 收入74.42亿元，同比下降11.93%；归属于上市公司股东的净利润为21.29亿元，同比下降20.74%；归属 于上市公司股东的扣除非经常性损益的净利润为18.91亿元，同比下降30.38%。 ...

Core Viewpoint - The company Pianzaihuang (600436.SH) has announced the initiation of Phase III clinical trials for its innovative traditional Chinese medicine, Wen Dan Pian, aimed at treating mild to moderate generalized anxiety disorder [1] Group 1: Clinical Trial Details - The Phase III clinical trial for Wen Dan Pian has successfully enrolled its first participant, marking the official start of the trial [1] - The trial is designed as a multicenter, randomized, double-blind, placebo-controlled study, focusing on the efficacy and safety of Wen Dan Pian [1] - The primary efficacy indicator for the trial is the change in HAMA score from baseline after 12 weeks of treatment [1] Group 2: Product Background - Wen Dan Pian is derived from the classic formula Wen Dan Tang, known for its effects in regulating qi, resolving phlegm, and calming the mind [1] - The product targets the specific syndrome of phlegm-heat disturbance, which is associated with anxiety disorders [1]

(本文来自第一财经) 片仔癀公告，2025年第三季度营收为20.64亿元，同比下降26.28%；净利润为6.87亿元，同比下降 28.82%。前三季度营收为74.42亿元，同比下降11.93%；净利润为21.29亿元，同比下降20.74%。 ...

格隆汇10月17日｜片仔癀(600436.SH)发布2025年第三季度财报显示，营业收入为20.64亿元，同比下降 26.28%，归属于上市公司股东的净利润为6.87亿元，同比下降28.82%。年初至报告期末，公司营业收入 为74.42亿元，同比下降11.93%，归属于上市公司股东的净利润为21.29亿元，同比下降20.74%。业绩减 少主要原因系本报告期医药制造业销售减少、毛利率下降所致。 ...

格隆汇10月17日丨片仔癀(600436.SH)公布，公司前三季度实现营业收入74.42亿元，同比下降11.93%； 归属于上市公司股东的净利润21.29亿元，同比下降20.74%；归属于上市公司股东的扣除非经常性损益 的净利润18.91亿元，同比下降30.38%；基本每股收益3.53元。 ...

证券代码：600436 证券简称：片仔癀 公告编号：2025-035 二、 公司 2025 年前三季度主营业务分类别情况 单位：万元 人民币 漳州片仔癀药业股份有限公司 2025年前三季度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上海证券交易所上市公司自律监管指引第3号——行业信息披 露（2022年修订）》《上海证券交易所上市公司行业信息披露指引第六 号——医药制造（2022年修订）》等相关法律法规，漳州片仔癀药业股 份有限公司（以下简称"公司"）现将2025年前三季度主要经营数据披 露如下： 一、 公司 2025 年前三季度主营业务分行业情况 单位：万元 人民币 | 行业 | 主营业务 收入 | 主营业务 成本 | 毛利率 （%） | 主营业务 收入增长 | 主营业务 成本增长 | 毛利率 增减情况 | | --- | --- | --- | --- | --- | --- | --- | | | | | | 率（%） | 率（%） | | | 医药制 造业 | 401,555.30 | 163 ...

漳州片仔癀药业股份有限公司关于温胆片Ⅲ期 临床试验完成首例受试者入组的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 漳州片仔癀药业股份有限公司（以下简称"公司"）温胆片Ⅲ 期临床试验完成首例受试者入组对公司本年度的财务状况和经营业 绩无重大影响。 证券代码：600436 证券简称：片仔癀 公告编号：2025-036 由于药品研发的特殊性，具有周期长、环节多、风险大、投入 高的特点，容易受到政策、技术、市场等多方面因素的影响，审评政 策及产品未来市场竞争形势等存在诸多不确定性风险。 公司将密切关注该药物研发事项的后续进展情况，及时履行信 息披露义务。敬请广大投资者谨慎决策，注意防范投资风险。 近日，公司研发的 1.1 类中药创新药温胆片完成"评价温胆片治 疗轻、中度广泛性焦虑障碍（痰热内扰证）有效性和安全性的多中心、 随机、双盲、安慰剂平行对照Ⅲ期临床试验"首例受试者入组，正式 进入Ⅲ期临床试验。现将相关内容公告如下： 一、药物的基本情况 药物名称：温胆片 剂型：片剂 规格：0.35g/片 注册分类：中药 ...